These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7837110)

  • 1. Actinomycin D for reinduction of remission in dogs with resistant lymphoma.
    Moore AS; Ogilvie GK; Vail DM
    J Vet Intern Med; 1994; 8(5):343-4. PubMed ID: 7837110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
    Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
    J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
    Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
    Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
    Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
    J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of tumor-bearing dogs with actinomycin D.
    Hammer AS; Couto CG; Ayl RD; Shank KA
    J Vet Intern Med; 1994; 8(3):236-9. PubMed ID: 8064663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
    Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
    J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
    Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
    J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
    Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
    J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
    Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
    J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
    Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
    J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
    Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
    Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
    Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
    J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
    Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
    J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.
    Mutsaers AJ; Glickman NW; DeNicola DB; Widmer WR; Bonney PL; Hahn KA; Knapp DW
    J Am Vet Med Assoc; 2002 Jun; 220(12):1813-7. PubMed ID: 12092954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
    Parsons-Doherty M; Poirier VJ; Monteith G
    Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
    ; ; . PubMed ID: 26004824
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.